BBO-8520's 65% ORR in KRAS G12C NSCLC positions BBOT for a potential registration path, contingent on whether combination data supports a differentiated efficacy and safety profile versus approved G12C inhibitors

Bull

A positive outcome would show deepened ORR and durable PFS in the combination arm that meaningfully exceeds the monotherapy 65% ORR benchmark, alongside a clean hepatotoxicity profile that contrasts favorably with the liver toxicity signals seen with sotorasib and adagrasib combinations with pembrolizumab. Strong activity in STK11/KEAP1 co-mutant patients — a historically immunotherapy-resistant and KRAS inhibitor-challenging subgroup — would further differentiate BBO-8520 and support a compelling registration strategy in first-line or immunotherapy-pretreated KRAS G12C NSCLC.

Bear

The most likely failure modes are hepatotoxicity at therapeutic doses when combined with pembrolizumab, a problem that derailed sotorasib-pembrolizumab development and limited adagrasib combinations, which would narrow the differentiation argument to efficacy alone. Alternatively, combination ORR and PFS could prove comparable to but not clearly superior to adagrasib or sotorasib monotherapy data, leaving BBOT without a compelling differentiating narrative needed to justify a registration-enabling trial versus already-approved agents.